Joanne Pinkerton

Marty McCary, the FDA Commissioner, discusses the agency's groundbreaking decision to remove the black box warning on estrogen therapy for menopause. Joanne Pinkerton, a menopause specialist, highlights the clinical benefits of hormone replacement therapy, especially when started early. They delve into how the 2002 Women's Health Initiative study led to a decline in therapy, and McCary reassesses the risks associated with hormone therapy. The conversation also addresses concerns about access and potential overuse after the warning's removal.